anti-HER2 antibody-drug conjugate DB-1303

An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC DB-1303, the antibody moiety targets and binds to HER2 on tumor cell surfaces. Upon cellular uptake and internalization, the cytotoxic agent inhibits tumor cell proliferation through an as of yet undisclosed mechanism of action (MoA). HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.